Baird reiterates Outperform rating on Lineage Cell stock after Roche R&D Day
PositiveFinancial Markets

Baird has reaffirmed its Outperform rating on Lineage Cell stock following Roche's recent R&D Day, indicating strong confidence in the company's future prospects. This endorsement is significant as it reflects Baird's belief in Lineage's innovative approaches and potential for growth in the biotech sector, which could attract more investors and boost stock performance.
— Curated by the World Pulse Now AI Editorial System